<DOC>
	<DOCNO>NCT00053625</DOCNO>
	<brief_summary>The purpose trial evaluate effect deep brain stimulation globus pallidus ( Gpi ) subthalamic nucleus ( STN ) motor , neuropsychological psychiatric function , quality life patient Parkinson 's disease .</brief_summary>
	<brief_title>Deep Brain Stimulation Parkinson 's Disease Trial</brief_title>
	<detailed_description>Medical therapy mainstay treatment patient Parkinson 's disease ( PD ) . After several year drug therapy , however , large proportion patient experience worsen parkinsonism develop incapacitate motor fluctuation dyskinesias . To deal , attention direct surgical procedure , deep brain stimulation ( DBS ) . Recently , stimulate area brain control movement , globus pallidus ( Gpi ) subthalamic nucleus ( STN ) , propose therapy treat many disable symptom associate PD drug-induced side effect . The major aim 5-year study carry prospective , double blind , randomize , clinical trial DBS medically intractable PD . The study evaluate effect DBS Gpi STN motor , neuropsychological psychiatric function , quality life patient PD . The study also address two key issue : 1 ) whether difference unilateral Gpi-DBS STN-DBS 2 ) patient best candidate bilateral DBS .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>INCLUSION : Clinical diagnosis Idiopathic Parkinson 's Disease base presence least 2 cardinal motor sign ( akinesia/bradykinesia , rigidity , tremor , gait/balance disorder ) clear response levodopa therapy . Hoeh &amp; Yahr stag III bad `` `` medication period . Intractable , disable motor fluctuation , dyskinesia , freeze episode . Unsatisfactory clinical response maximal medical management previous surgical treatment . Stable Parkinson 's medication least 30 day total Ldopa equivalence vary +/ twenty percent 30 day period . Absence cognitive , psychiatric comorbidities might interfere patient 's ability understand sign inform consent form . EXCLUSION : Clinically significant medical history increase pre / post operative complication ( Cardiac pulmonary disease , uncontrolled hypertension , diabetesâ€¦ ) . Secondary atypical parkinsonism suggest : . History stroke , encephalitis , exposure toxin neuroleptic . ii . Neurologic sign upper motor neuron cerebellum involvement , supranuclear gaze palsy , significant autonomic dysfunction . iii . MRI scan evidence significant brain atrophy , lacunar infracts , iron deposit putamen . Dementia indicate Mattis Dementia Rating Scale ( DRS ) less 116 DSMIV criterion dementia . Clinically significant psychiatric disorder meeting Structured Clinical Interview DSMIV criterion active anxiety , depressive , psychotic disorder .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>PD</keyword>
	<keyword>deep brain stimulation</keyword>
	<keyword>DBS</keyword>
</DOC>